Scorpius Holdings Inc. (SCPX) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. There were no new wire items for SCPX in the last 30 days. The most recent was published Mar 19, 2026.
Latest news
25 items- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECAmendment: Scorpius Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Events That Accelerate or Increase a Direct Financial Obligation8-K/A - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECSEC Form 10-Q filed by Scorpius Holdings Inc.10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Events That Accelerate or Increase a Direct Financial Obligation8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECSEC Form 10-Q filed by Scorpius Holdings Inc.10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECSEC Form NT 10-Q filed by Scorpius Holdings Inc.NT 10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- PRTivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA SubmissionTivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec
- SECSEC Form 424B3 filed by Scorpius Holdings Inc.424B3 - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- PRScorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast AsiaOperational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr
- SECScorpius Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECScorpius Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECSEC Form 25-NSE filed by Scorpius Holdings Inc.25-NSE - Scorpius Holdings, Inc. (0001476963) (Subject)
- PRScorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational StreamliningSAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id
- SECSEC Form 10-K filed by Scorpius Holdings Inc.10-K - Scorpius Holdings, Inc. (0001476963) (Filer)
- SECSEC Form RW filed by Scorpius Holdings Inc.RW - Scorpius Holdings, Inc. (0001476963) (Filer)
SCPX FAQ
5 questionsWhat is the latest news on SCPX?
Quantisnow has not tracked any new filings, ratings or press releases for SCPX in the last 30 days. The most recent wire item was published on March 19, 2026.Where does SCPX stock trade?
Scorpius Holdings Inc. (SCPX) is listed on AMEX.What sector and industry is SCPX in?
Scorpius Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SCPX?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare SCPX side-by-side with any of them on Quantisnow.How can I track SCPX on Quantisnow?
Quantisnow aggregates Scorpius Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCPX to receive live email and push alerts on every new disclosure.